The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors.
Jin Li
No relevant relationships to disclose
Junning Cao
No relevant relationships to disclose
Jian Zhang
No relevant relationships to disclose
Songhua Fan
Employment or Leadership Position - Hutchison MediPharma
Yang Sai
Employment or Leadership Position - Hutchison MediPharma
Hua MU
Employment or Leadership Position - Hutchison MediPharma